Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291108 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT01291108 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 125 participants.
The verdict
NCT01291108, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG bimatoprost
- DRUG AGN-210669
- DRUG bimatoprost vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01291108
The ClinicalTrials.gov registry entry for NCT01291108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bimatoprost is the first listed.
NCT01291108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01291108 about?
NCT01291108 is a clinical study titled "Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension". This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT01291108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2011-04. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01291108?
The interventions under investigation include: bimatoprost (DRUG), AGN-210669 (DRUG), bimatoprost vehicle (DRUG).
Who is sponsoring clinical trial NCT01291108?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.